Agonists of A2A adenosine receptors for treatment of...

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S043000, C514S048000

Reexamination Certificate

active

07396825

ABSTRACT:
The present invention provides a therapeutic method for treating diabetic kidney disease, e.g., diabetic nephropathy that includes the administration of an effective amount of an A2Aadenosine receptor agonist. Optionally, the method includes administration of a type IV PDE inhibitor.

REFERENCES:
patent: 6531457 (2003-03-01), Linden et al.
patent: WO-2005/107463 (2005-11-01), None
Okusa et al. Kidney International (2001), vol. 59, pp. 2114-2125.
Pflueger et al. Am. J. Physiol Renal Physiol. (1999), vol. 276, pp. 340-346.
“International Search Report for Application No. PCT/US05/15241”, (Aug. 19, 2005),3 pgs.
Okusa, M D., “Enhanced Protection from Renal Ischemia: Reperfusion Injury With A2A-Adenosine Receptor Activation and PDE 4 Inhibition”,Kidney International, 59(6), (2001),2114-2125.
Okusa, Mark D., “Selective A2A adenosine receptor activation reduces ischemia-reperfusion injury in rat kidney”,Am. J. Physiol., vol. 277 (3, Pt 2), (1999),F404-F412.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Agonists of A2A adenosine receptors for treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Agonists of A2A adenosine receptors for treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agonists of A2A adenosine receptors for treatment of... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2787980

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.